

## Acute Coronary Syndromes Committee meeting 8

**Date:** 30/4/2019

**Location:** National Guideline Centre, Royal College of Physicians London,  
11 St Andrews Place, Regent's Park, London NW1 4LE

**Minutes:** Final

<b>Committee members present:</b>		
Margaret Lally (Chair)		(Present for notes 1 – 10)
Simon Corbett (Topic adviser)		(Present for notes 1 – 10)
Farrah Al-Ghita		(Present for notes 1 – 10)
Christopher Cassidy		(Present for notes 1 – 10)
Ewan Gittins		(Present for notes 1 – 10)
Lance Goodman		(Present for notes 1 – 10)
Muhammad Murad Khan		(Present for notes 1 – 10)
Alun Roebuck		(Present for notes 1 – 10)
Alex Sharp		(Present for notes 1 – 10)
Neil Swanson		(Present for notes 1 – 10)

<b>In attendance:</b>		
Rupert Franklin	Senior Guidelines Commissioning Manager	(Present for notes 1 – 10)
Jill Cobb	Information Specialist	(Present for notes 8)
Annabelle Davies	Health Economist	(Present for notes 1 – 10)
Saoussen Ftouh	Senior Research Fellow	(Present for notes 1 – 10)
Bernard Higgins	Clinical Director & Guideline Lead	(Present for notes 1 – 10)
Sedina Lewis	Senior Research Fellow	(Present for notes 1 – 10)
Kate Lovibond	Health Economics Lead	(Present for notes 7 - 10)
Nancy Pursey	Senior Project manager	(Present for notes 1 – 10)

**Apologies:**

Jaydeep Sarma	Committee member
Agnes Cuyas	Information Specialist, NGC

### **1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the 8th meeting of the Acute coronary syndromes guideline committee. The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Provide an update on changes to the project timeline and future committee meetings
- Review the evidence for choice of anti-thrombin agents in patients with non-ST elevation myocardial infarction (NSTEMI) and unstable angina.
- Presentation of the results of the network meta-analysis conducted for the review of choice of anti-platelet agents for managing unstable angina, NSTEMI or ST elevation myocardial infarction (STEMI).
- Agree protocol for the review of combination of antiplatelet and anticoagulation therapy
- Provide an update on the model for anti-platelets.

### **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were choice of anti-thrombin therapy, choice antiplatelet therapy and combinations of antiplatelet and anti coagulation in people with ACS and a separate indication for anticoagulation.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were declared. Alun Roebuck confirmed that he had declined a request to carry out work for Astra Zeneca.

The Chair and Guideline lead noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Minutes of last meeting**

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate

account of the meeting.

#### **4. Update**

The Chair gave an update on the project timeline and changes to future committee meetings.

#### **5. Presentation**

The Chair introduced Saoussen Ftouh, Senior Research Fellow, and Annabelle Davies, Health Economist, who gave a presentation on the clinical and cost effectiveness evidence for the following review question: What is the optimal choice of antithrombin therapy in adults with unstable angina or NSTEMI who are being considered for coronary angiography within 24 hours of admission?

The Committee then discussed the evidence and draft recommendations.

#### **6. Patient decision aids**

The Chair explained the possible approaches and potential topics for developing a decision aid. This will be revisited at a future meeting when the committee has seen all of the evidence.

#### **7. Presentation**

The Chair introduced Sedina Lewis, Senior Research Fellow, who gave a presentation on the results of the network meta-analysis conducted for the review question: which antiplatelet is most clinically and cost effective for managing unstable angina or NSTEMI or for managing STEMI in adults?

#### **8. Draft protocol discussion**

The Chair introduced Saoussen Ftouh, Senior Research Fellow, who led a discussion on the protocol, for the review question: What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and an indication for anticoagulation?

The committee discussed changes to the draft protocol.

#### **9. Presentation**

The Chair introduced Annabelle Davies, Health Economist, who gave a presentation on the modelling methods for the antiplatelet model.

#### **10. Any other business**

None

**Date of next meeting:** 18/06/2019

**Location of next meeting:** Holiday Inn Regent's Park, London